BNP Paribas Exane Issues Pessimistic Forecast for Zoetis (NYSE:ZTS) Stock Price

Key Points

• BNP Paribas Exane cut Zoetis’ price target from $146 to $110 but maintained an “outperform” rating, implying 46.6% upside from the stock’s prior close.
• Analyst sentiment has grown more cautious: several brokerages lowered their targets, and Zoetis carries an overall “Hold” rating with an average target of $110.85.
• Zoetis recently beat quarterly EPS expectations, reporting $1.87 versus $1.85, though revenue declined slightly year over year. The stock traded near $75, close to its 52-week low, amid concerns about slower growth and competitive pressures.

Zoetis (NYSE:ZTS - Get Free Report) had its price target reduced by BNP Paribas Exane from $146.00 to $110.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. BNP Paribas Exane's price target indicates a potential upside of 46.62% from the stock's previous close.

Several other brokerages have also commented on ZTS. Wall Street Zen lowered shares of Zoetis from a "buy" rating to a "hold" rating in a research note on Saturday, May 2nd. Piper Sandler decreased their price objective on Zoetis from $90.00 to $80.00 and set a "neutral" rating for the company in a report on Monday. Weiss Ratings cut Zoetis from a "sell (d+)" rating to a "sell (d)" rating in a research report on Friday, June 12th. JPMorgan Chase & Co. lowered their target price on Zoetis from $130.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday. Finally, TD Cowen decreased their target price on shares of Zoetis from $150.00 to $104.00 and set a "buy" rating for the company in a research report on Tuesday, June 30th. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of "Hold" and an average target price of $110.85.

Zoetis Stock Performance

ZTS traded up $0.19 during trading on Tuesday, reaching $75.02. 2,047,818 shares of the company were exchanged, compared to its average volume of 5,795,127. Zoetis has a 52 week low of $71.45 and a 52 week high of $160.48. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The firm has a 50 day moving average of $76.60 and a 200 day moving average of $100.24. The stock has a market cap of $31.45 billion, a P/E ratio of 12.36, a PEG ratio of 1.21 and a beta of 0.73.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to analysts' expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm's quarterly revenue was down .2% compared to the same quarter last year. During the same period last year, the business posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts forecast that Zoetis will post 6.43 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Frank A. Damelio acquired 6,650 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares of the company's stock, valued at $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Paul Bisaro bought 2,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.22% of the company's stock.

Institutional Trading of Zoetis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its stake in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after buying an additional 2,978 shares in the last quarter. Empowered Funds LLC increased its position in shares of Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company's stock worth $1,859,000 after purchasing an additional 657 shares in the last quarter. Intech Investment Management LLC lifted its holdings in Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company's stock valued at $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC boosted its position in Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company's stock valued at $522,000 after buying an additional 1,422 shares in the last quarter. Finally, Glenview Trust co increased its stake in shares of Zoetis by 11.8% in the second quarter. Glenview Trust co now owns 4,780 shares of the company's stock valued at $745,000 after buying an additional 506 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis continues to generate strong earnings and profitability. Its latest quarterly EPS exceeded expectations, while its net margin and return on equity remain substantial. Analysts’ targets still imply upside from recent levels, suggesting some view the selloff as excessive. Zoetis stock: Is Wall Street bullish or bearish?
• Neutral Sentiment: JPMorgan lowered its Zoetis price target to $115, but the revised target remains materially above the recent trading level. The adjustment indicates more cautious valuation assumptions rather than an outright bearish view. JPMorgan cuts Zoetis price target
• Negative Sentiment: Piper Sandler reduced its price target from $90 to $80 and assigned a neutral rating. Although the new target represents potential upside, the cut reinforces concerns that Zoetis’ growth and valuation outlook have weakened. Piper Sandler lowers Zoetis price target
• Negative Sentiment: Recent analysis highlights leadership transitions and competitive pressures as factors shaping Zoetis’ guidance. Investors appear concerned that these issues could limit growth despite the company’s resilient earnings performance. ZTS Q2 deep dive
• Negative Sentiment: Commentary asking what went wrong at Zoetis reflects a broader reassessment of the former growth leader. Slower revenue performance, competitive concerns and reduced expectations have weakened investor sentiment. Zoetis looked like a winner: What went wrong?
• Negative Sentiment: Zoetis’ incoming finance chief will assume responsibilities combining CFO and COO duties. While the broader mandate could improve operational coordination, the unusual transition adds execution risk while the company is already facing growth and competitive challenges. Boards expand CFO mandates

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source